Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

evobrutinib

- PMLiVE

Solid performance for Merck KGaA in “transformation year”

Sales and profits on track amid job cuts and restructuring

- PMLiVE

Late-stage failure for Merck’s cilengitide in brain cancer

Integrin inhibitor unable to improve overall survival in phase III trials

- PMLiVE

Biogen gains full rights to Tysabri in $3.25bn deal with Elan

Ends decade-long partnership for MS drug

- PMLiVE

Merck KGaA and Opexa enter MS deal

Will develop personalised T-cell based medicine Tcelna

- PMLiVE

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales

- PMLiVE

Merck KGaA starts third phase III trial for cancer hope TH-302

Unique method of action to target cells with low oxygen levels

- PMLiVE

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

- PMLiVE

Merck’s oncology vaccine fails lung cancer trial

Stimuvax unable to demonstrated improvement in overall survival

- PMLiVE

Merck KGaA picks Constantin Fest to lead investor relations

He succeeds Joshua Young who will leave the company and move to the US

- PMLiVE

Merck raises guidance on solid Q3 sales

Rebif gains boost pharma division

- PMLiVE

EFPIA offers to cap Greek drug costs as debts escalate

Comes as Merck KGaA halts Erbitux supplies over unpaid bills

- PMLiVE

Merck KGaA acquires cancer drug from Symphogen

Will pay up to €495m for investigational metastatic colorectal cancer treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links